Viagra Ingredient Sildenafil May Help Treat A Rare And Fatal Childhood Disease, Leigh Syndrome

For decades, Sildenafil has been widely recognised as the key ingredient in Viagra, primarily used to treat erectile dysfunction and certain cases of pulmonary hypertension. But new research suggests this well-known drug may have an entirely different, and potentially life-saving, role in treating a rare and often fatal childhood disease. A recent study published in the journal Cell has found that sildenafil could significantly improve symptoms in patients with Leigh syndrome, a severe genetic disorder that affects the brain and muscles. Traditionally considered untreatable, Leigh syndrome typically appears in infancy or early childhood and progressively worsens, often leading to early death.

What makes this discovery particularly compelling is that sildenafil is already widely studied and approved for other uses, meaning its safety profile is relatively well understood. Researchers believe this could accelerate the path toward a viable treatment option for a disease that currently has none.

While the findings are still preliminary and based on a small group of patients, experts say they mark a major breakthrough in rare disease research, offering new hope to families affected by this devastating condition.

What The Study Found

According to researchers from Charite - Universitatsmedizin Berlin, sildenafil showed promising results in improving symptoms of Leigh syndrome in a small pilot study involving six patients. Patients treated with the drug experienced stronger muscle function, fewer seizures, and improved recovery from metabolic crises, dangerous episodes where the body's energy system fails.

"For example, in the case of a child undergoing sildenafil treatment, the walking distance increased tenfold...," said Prof Markus Schuelke, one of the study's lead authors. He added, "Such effects significantly improve the quality of life of Leigh syndrome patients... we are very pleased to have found a promising drug candidate."

Understanding Leigh Syndrome

Leigh syndrome is a genetic metabolic condition caused by defects in mitochondria, the energy-producing parts of cells. Because the brain and muscles require high energy, they are most affected. Symptoms typically begin in infancy or early childhood and may include:

• Muscle weakness and loss of movement
• Seizures
• Developmental delay
• Difficulty swallowing and breathing
• Paralysis

The disease is progressive and often fatal, with many children not surviving beyond a few years after diagnosis. It affects approximately 1 in 36,000 children, making it a rare but devastating condition.

Why Sildenafil Works: The Science Behind It

Sildenafil belongs to a class of drugs called PDE-5 inhibitors, which work by relaxing blood vessels and improving blood flow. However, researchers discovered that its benefits may extend beyond vascular effects. In laboratory studies using patient-derived nerve cells, sildenafil improved cellular energy function and enhanced electrical activity in neurons.

Further experiments in brain organoids and animal models showed that the drug:

• Boosted nerve cell growth
• Improved mitochondrial function
• Extended lifespan in disease models

These findings suggest sildenafil may help cells better cope with energy deficits, a core problem in Leigh syndrome.

From Lab To Patients: Real-World Impact

Encouraged by laboratory results, researchers administered sildenafil to six patients aged between 9 months and 38 years. Within months, several showed measurable improvements.

Some patients experienced:

• Reduced or eliminated seizures
• Improved mobility and endurance
• Faster recovery from metabolic crises

"Another decisive factor was... safety data... for long-term use of sildenafil in children," noted Prof Alessandro Prigione, highlighting why the drug was chosen for clinical use. Importantly, the treatment was generally well tolerated, adding to its potential as a future therapy.

Why Rare Diseases Are Hard To Treat

Rare diseases like Leigh syndrome present unique challenges. Due to the small number of patients, conducting large clinical trials is difficult. "The low case numbers make it difficult to research the disease...," explained Prof Schuelke. To overcome this, researchers used advanced techniques such as stem-cell-derived brain models and large-scale drug screening, testing over 5,500 compounds before identifying sildenafil as a promising candidate.

What Happens Next?

While the results are encouraging, experts stress that this is still early-stage research. Larger, placebo-controlled clinical trials are now planned across Europe to confirm the findings. The European Medicines Agency has already granted sildenafil "orphan drug" status for rare diseases, which could help speed up development and approval.

If successful, sildenafil could become the first effective treatment for Leigh syndrome, a major milestone in paediatric neurology.

Disclaimer: This content, including advice, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.